Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.

Autor: Gregory Y H Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak

Publikováno v: PLoS ONE, Vol 13, Iss 4, p e0195950 (2018)

Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF) patients to an increased risk of stroke. This study describes the real-world discontinuation rates and compared the risk of drug discontinuation among NVAF pati

Externí odkaz: https://doaj.org/article/1d91d2e9b21b4beaa5b2bfa6fbd15d9f

Prevalence of Co-existing Autoimmune Disease in Rheumatoid Arthritis: A Cross-Sectional Study

Autor: Anagha Baheti, Samy Suissa, Teresa A. Simon, John M. Esdaile, Hugh Kawabata, Nitesh Ray

Publikováno v: Advances in Therapy

Introduction Many autoimmune diseases, including rheumatoid arthritis (RA), share common mechanisms; however, population-based studies of the magnitude of multiple autoimmune diseases in patients with RA have not been performed. Methods We conducted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c03e57156b24c54d536dfb201017534
http://europepmc.org/articles/PMC5702376

The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation

Autor: Han-Yao Huang, Hugh Kawabata, Teresa A. Simon, Xianying Pan, Laurent Azoulay

Publikováno v: Cardiovascular Therapeutics

Summary Aim While bleeding is a well-known complication of warfarin use and is thought to be a contributory cause of treatment discontinuation, studies quantifying this association are limited. The objective of this study was to quantify the associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb81857ff28edda361bb16785fc0cb02
http://europepmc.org/articles/PMC4849207

Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors

Autor: Andres Gomez, Hugh Kawabata, Brian Dreyfus

Publikováno v: Cancer Epidemiology. 37:191-196

Introduction : To evaluate the safety profile of new drugs, it is important to quantify the rates of adverse events (AE). There has been little to no research on the safety of vascular endothelial growth factor (VEGF) inhibitors in population-based s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea0ea4cf0dc7675695bc8c6c040c358
https://doi.org/10.1016/j.canep.2012.11.001

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin:a 'real-world' observational study in the United States

Autor: Jack Mardekian, Shital Kamble, Xianying Pan, Gregory Y.H. Lip, Cristina Masseria, Hemant Phatak, Amanda Bruno, Hugh Kawabata

Publikováno v: Lip, G Y H, Pan, X, Kamble, S, Kawabata, H, Mardekian, J, Masseria, C, Bruno, A & Phatak, H 2016, ' Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin : a "real-world" observational study in the United States ', International Journal of Clinical Practice, vol. 70, no. 9, pp. 752-763 . https://doi.org/10.1111/ijcp.12863
International Journal of Clinical Practice

BACKGROUND: Limited data are available about the real-world safety of non-vitamin K antagonist oral anticoagulants (NOACs).OBJECTIVES: To compare the major bleeding risk among newly anticoagulated non-valvular atrial fibrillation (NVAF) patients init

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35260ca33e6d20144e701d80b7e813f9
https://vbn.aau.dk/da/publications/7229c2cf-c339-4965-ad92-1f6ced3f9df4